NCT04940299 2026-03-06
Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
Clinical Trials
10 trialsNCT03873818 2026-01-09
Low Dose Ipilimumab With Pembrolizumab in Treating Patients With Melanoma That Has Spread to the Brain
M.D. Anderson Cancer Center
Phase 2 Completed
NCT05428007 2026-01-05
Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma
NYU Langone Health
Phase 2 Recruiting
NCT01950390 2025-12-11
Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 2 Completed
NCT07155317 2025-11-12
Time-of-Day Specified Immunotherapy for Advanced Melanoma, The TIME Trial
Emory University
Phase 2 Recruiting
NCT03396952 2022-10-13
Prostaglandin Inhibition and Immune Checkpoint Blockade in Melanoma
University of California, San Francisco
Phase 2 Completed
NCT01970527 2020-02-13
Phase II Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Treating Patients With Stage IV Melanoma
University of Washington
Phase 2 Terminated
NCT02158520 2020-01-21
Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery
Academic and Community Cancer Research United
Phase 2 Completed
NCT03220009 2018-10-03
Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma
National Cancer Institute (NCI)
Phase 2 Withdrawn
NCT00050102 2011-01-28
Comparison Study of MDX-010 (CTLA-4) Alone and Combined With DTIC in the Treatment of Metastatic Melanoma
Bristol-Myers Squibb
Phase 2 Completed